Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Techne Corporation (NASDAQ: TECH) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Bio-Techne’s life sciences business, which focuses on tools, bioactive reagents, diagnostics, and spatial biology products for research and clinical diagnostic communities.
Investors can review current reports on Form 8-K, where Bio-Techne discloses material events such as quarterly and annual financial results and the declaration of cash dividends. For example, recent 8-K filings reference press releases describing results of operations, financial condition, and dividend announcements. These documents help readers understand revenue trends, segment performance for the Protein Sciences and Diagnostics and Spatial Biology segments, and key corporate actions.
Bio-Techne’s proxy statements on Schedule 14A provide insight into corporate governance, board composition, executive compensation, and shareholder proposals. The company’s definitive proxy statement discusses its mission to improve the quality of life by catalyzing advances in science and medicine, outlines its four growth pillars, and describes how the board oversees strategy, risk, and sustainability initiatives, including greenhouse gas emission reduction commitments.
Annual and quarterly reports on Forms 10-K and 10-Q, when accessed through EDGAR, contain segment disclosures, risk factors, and management’s discussion and analysis relevant to Bio-Techne’s life science tools and diagnostics operations. Filings related to shareholder meetings also detail voting results on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
On Stock Titan, these TECH filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand what changed and why it matters. Real-time updates from EDGAR, combined with structured access to 8-Ks, proxy statements, and other filings, make this page a useful resource for tracking Bio-Techne’s regulatory disclosures and governance information.
Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.
Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.
Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.
Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).
Bio-Techne Corp (TECH) reported an insider equity transaction by a director. On 10/30/2025, the reporting person acquired 1,640 shares of common stock at $0 and received a grant of stock options for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035.
After these transactions, the director directly beneficially owns 8,775 shares of common stock. The option grant vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director Alpna Seth reported insider transactions. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing her direct holdings to 15,411 shares. She also received a new stock option grant for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one-year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH): Form 4 insider update. Director Amy E. Herr reported an equity grant on 10/30/2025. She acquired 1,640 shares of common stock at $0, bringing direct holdings to 2,680 shares; an additional 2,154 shares are held indirectly by a significant other.
She was also granted a stock option to buy 3,777 shares at $60.96, expiring 10/30/2035; vesting occurs on the earlier of the one‑year anniversary of the grant or the 2026 annual meeting. The filing also lists previously awarded options and restricted stock units held indirectly with specified vesting schedules.
Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing direct holdings to 3,782 shares.
She was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring 10/30/2035. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders. Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).
Bio‑Techne (TECH)1,640 shares of common stock on 10/30/2025 at a reported price of $0, bringing direct beneficial ownership to 10,987 shares after the transaction.
The filing also lists a new derivative award: 3,777 stock options acquired on 10/30/2025 with an exercise price of $60.96 and an expiration date of 10/30/2035. According to the footnote, the option vests on the earlier of the one‑year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director Robert V. Baumgartner reported insider activity. On 10/30/2025, he acquired 1,640 common shares at $0, bringing his directly held shares to 46,503 after the transaction. He was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.